Navigation Links
BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board
Date:10/14/2008

- Pioneer in High Throughput SNP Discovery Brings Expertise in Human Genome Haplotyping -

PHILADELPHIA, Oct. 14 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for genetic diagnostics, personalized medicine and biomedical research, today announced the appointment of noted medical genomics researcher Pui-Yan Kwok, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Kwok is Henry Bachrach Distinguished Professor at the University of California, San Francisco.

Dr. Kwok's research is focused on the development of new approaches to whole genome analysis and their application to gene mapping and haplotyping. He pioneered the high throughput discovery of single nucleotide polymorphisms (SNPs) across the human genome and was a member of the International HapMap Consortium Steering Committee. The inventor of several fluorescence-based SNP genotyping methods, Dr. Kwok more recently has been developing mapping and haplotyping methods based on microscopic analysis of single DNA molecules. He has authored over 110 publications and holds three patents.

"Pui-Yan has extensive experience in single-molecule DNA mapping and haplotyping, both as a distinguished research leader and as an inventor of novel genotyping methods," said Dr. Han Cao, chief scientific officer of BioNanomatrix. "His expertise should be especially valuable as we further develop our platform to image and analyze individual DNA molecules for the high-resolution mapping of labeled genomic sites, a project which is supported by a recent NIH grant to BioNanomatrix."

BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project in partnership with Complete Genomics, Inc. for low-cost sequencing of the human genome

"BioNanomatrix's single-molecule technology has the potential to transform whole genome imaging, enabling researchers to assemble haplotype maps with valuable contextual information much faster and more cost effectively in reliable standardized formats than with existing methods," said Dr. Kwok. "I look forward to working with the BioNanomatrix team to contribute to the development of this promising new approach, which could add to the understanding of complex genetic diseases by greatly increasing access to whole genome analysis."

Professor Kwok received Ph.D. and M.D. degrees from the University of Chicago. After completing his residency training at Washington University Medical Center, he was a postdoctoral fellow at Washington University and a visiting scientist at the University of Washington.

About BioNanomatrix

BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in genetic diagnostics, personalized medicine and biomedical research. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project to sequence the human genome at a cost of $100. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania. For more information, visit: http://www.BioNanomatrix.com.

Contact:

Barbara Lindheim

GendeLLindheim BioCom Partners

212 918-4650


'/>"/>
SOURCE BioNanomatrix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
2. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
3. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
4. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
5. BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board
6. BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):